Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of mirikizumab in pediatric ulcerative colitis and Crohn's disease
2020-005311-49Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in autoimmune colitis and Crohn's disease, sponsored by Eli Lilly and Company. Primary endpoints: Long-term efficacy in Crohn's disease ISA and Long-term safety in Crohn's disease ISA. Started Jul 2022; status: active.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2020-005311-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005311-49.